Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities

NEXT STORY
Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer
PREV STORY
Cyclacel Pharmaceuticals to Release Second Quarter 2019 Financial Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

MacroGenics Provides Update on Corporate Progress and Second Quarter 2017 Financial Results

ROCKVILLE, Md., Aug. 02, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical ...

author_avatar
NASDAQ Market News

Cancer Genetics Receives Non-Dilutive Funding of $1.1 Million through New Jersey Technology Business Tax Certificate Transfer (NOL) Program

RUTHERFORD, N.J., Dec. 28, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader ...

author_avatar
NASDAQ Market News

Publishing of Orion Corporation’s Half-Yearly Report for January-June 2016 on 19 July 2016

ORION CORPORATION     STOCK EXCHANGE RELEASE   5 JULY 2016 at 9:00 A.M. EEST Publishing of ...

author_avatar
NASDAQ Market News